iScience: A potential way to combat inherited neurological disorders

Scientists at the National Center for The Advancement of Translational Science (NCATS) at the Icahn School of Medicine in Mount Sinai, New York, and other researchers have reversed the effects

The research team, led by Dr.

Dr Ioannou is Professor of Genetics and Genomic Sciences at Icahn School of Medicine at

LSDs are characterized by genetic defects that prevent the lysosomes of cells from breaking down and circulating fats, sugars, and proteins, causing them to accumulate in organs, including the liver and brain

What is this study trying to reveal? Researchers have long been looking for drugs that can affect lysosomals, trying to influence lysosomal storage diseases

Conclusion: The data suggest that mitochondrial TRAP1 is a potential new therapeutic target for a variety of diseases

Why is this research important? The researchers say the findings could have implications for other neurodegenerative diseases with similar underlying causes, such as Parkinson's, amyotrophic lateral sclerosis and Alzheimer's

How was this research conducted? Dr.

They found that compounds that activate TRAP1 get the mitochondria back to function and restart the circulating capacity of the lysosomes, helping to reduce fat

Next: Scientists hope to learn more about how these compounds reverse the characteristics of lysosomal storage disease, which will help develop potential drug treatments

essay

Activating mitochondrial TRAP1 stimulates mitochondrial-lysosomal crosstalk and corrects lysosomal dysfunction